|Articles|July 27, 2023
DIA 2023: What is Biofourmis Currently Working on with CancerX?
Jaydev Thakkar, chief operating officer, Biofourmis discusses the work his organization is doing within the CancerX initiative at the 2023 DIA annual meeting in Boston, MA.
Advertisement
In an interview at the 2023 DIA annual meeting with ACT editor, Andy Studna, Jaydev Thakkar, chief operating officer, Biofourmis, disucsses how Biofourmis is working with CancerX to address the financial burden cancer treatment can place on patients.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
FDA Approves Imfinzi Plus FLOT for Early and Locally Advanced Gastric and GEJ Cancers
2
Is Artificial Intelligence Coming for Clinical Research?
3
Novo Nordisk Submits Higher-Dose Wegovy Injectable for FDA Approval with Priority Voucher
4
FDA Clears Itvisma as First Gene Therapy for Adolescents and Adults With SMA
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
